# Rivaroxaban

## XARELTO 15mg

##### 

| 標題       | 說明                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|:-----------|:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 藥品代碼   | OXAR                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| 適應症     | Xarelto 10 mg Prevention of Venous Thrombosis(VTE) in adult patients undergoing elective hip or knee replacement surgery. Xarelto 15 mg & 20 mg Prevention of stroke & systemic embolism in adult patients w/ non-valvular atrial fibrillation w/ ≧1 risk factors eg CHF, HTN, age ≧75 yr, DM, prior stroke or transient ischaemic attack. Treatment of Deep Venous Thrombosis (DVT) & PE, & prevention of recurrent DVT & PE following an acute DVT in adults. |
| 用法用量   | Prevention of stroke and systemic embolism for patients with non-valvular atrial fibrillation: 15-20mg QD.(Clcr > 50 mL/min). Deep vein thrombosis(DVT), pulmonary embolism(PE) treatment and prophylaxis: 15mg BID on day 1-21, followed by 20mg QD from day 22. Prophylaxis of VTE high risk patient: 10mg QD.                                                                                                                                                |
| 肝功能異常 | 需調整劑量                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| 腎功能異常 | 需調整劑量                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| 禁忌       | Hypersensitivity. Clinically significant active bleeding. Hepatic disease associated w/ coagulopathy & clinically relevant bleeding risk including cirrhotic Child-Pugh B & C patients. Pregnancy & lactation.                                                                                                                                                                                                                                                  |
| 副作用     | Anemia, dizziness, headache, syncope, eye haemorrhage, tachycardia, hypotension, haematoma, epistaxis, GI disorders, pruritus, pain in extremity, urogenital tract haemorrhage, fever, peripheral oedema, decreased general strength & energy, increased transaminases, postprocedural haemorrhage.                                                                                                                                                             |
| 孕期建議   | No (limited) human data – animal data suggest moderate risk                                                                                                                                                                                                                                                                                                                                                                                                     |
| 哺乳期建議 | No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用                                                                                                                                                                                                                                                                                                                                                                                            |

## Xarelto 2.5mg

##### 

| 標題       | 說明                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|:-----------|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 藥品代碼   | OXAR25                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| 適應症     | Cardiovascular event risk; Prophylaxis of Peripheral arterial occlusive disease and Coronary arteriosclerosis, In combination with aspirin.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| 用法用量   | Prophylaxis of CAD and PAD: 2.5mg BID combined with aspirin 100mg QD. This regimen should not be used when acute thrombosis happened.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| 肝功能異常 | 需調整劑量                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| 腎功能異常 | 需調整劑量                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| 禁忌       | Active pathological bleeding. Severe hypersensitivity reaction (eg, anaphylaxis) to rivaroxaban. Patients with severe hepatic impairment or with any degree of hepatic disease associated with coagulopathy. Patients with severe progressive bleeding (such as intracranial hemorrhage, gastrointestinal hemorrhage). PREGNANCY and BREASTFEEDING. Patients with CrCl <15 mL/min.                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| 副作用     | Common Hematologic: Hemorrhage (DVT prophylaxis following hip or knee replacement, 5.8%; treatment of DVT or pulmonary embolism, 28.3%; reduction in risk of recurrence of DVT or pulmonary embolism, 13.4% ; prophylaxis of VTE in acutely ill medical patients, 2.9% ) Serious Cardiovascular: Syncope (1.2% ) Gastrointestinal: Gastrointestinal hemorrhage (0.5% to 2% ), Upper gastrointestinal bleeding Hematologic: Hematoma, Epidural or spinal, Hemorrhage, Major (Stroke prevention in nonvalvular atrial fibrillation, 3.6%; DVT prophylaxis following hip or knee replacement, 0.3%; treatment of DVT or pulmonary embolism, 1%; reduction in risk of recurrence of DVT or pulmonary embolism, 0.4%; prophylaxis of VTE in acutely ill medical patients, 0.7% ) Immunologic: Angioedema Other: Drug withdrawal, Stroke and non-CNS embolism. |
| 孕期建議   | No (limited) human data – animal data suggest moderate risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| 哺乳期建議 | No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |

